OMC Healthcare develops, manufacture, and promote innovative in-vitro diagnostics in the field of rapid diagnostic tests and molecular diagnostic products.
Our dedication and effort in R&D have led us in developing and launching new products every year and brought us a step closer to satisfying our customers’ demand. Since 2011, OMCH is trying to meet the market demands for accurate and cost-effective in vitro diagnosis at a whole new level of technology and product development. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, biomedical research, agrigenomics and animal and food safety.
We operate on an ISO 9001, ISO 13485 certified and WHO GMP compliance facility under Full Quality Assurance Systems.
OMC Healthcare (Pvt.) Ltd. took an initiative to develop the first made in Bangladesh RT-PCR test kit for the diagnosis of COVID-19. The kit is the first one to receive approval for production and commercial use from Directorate General of Drug Administration (DGDA), Bangladesh on 3rd January 2021;
The kit has utilized primers and probes targeting two specific conserved sequence N1 and N2 of coding nucleocapsid protein N gene, both of which have been acknowledged as target gene markers for molecular detection of COVID-19 by WHO and CDC guidelines. As per WHO guideline, kits using these two genes are fully capable of catching the new variant of COVID-19. As such, this kit can be one of Bangladesh’s principal weapons in effective diagnosis and clinical management of COVID-19.
OMCH Site Map
Business
Contact us